Matthias Wolfgang Heinzl

Dr. Matthias Wolfgang Heinzl

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2020 in Infection and Immunity
Verified
Journal Article
Open access
PDF file
MHMatthias Wolfgang Heinzl
Matthias Wolfgang Heinzl
MRMichael Resl
Michael Resl
CKCarmen Klammer
Carmen Klammer
MEMargot Egger
Margot Egger
BDBenjamin Dieplinger
Benjamin Dieplinger
MCMartin Clodi
Martin Clodi
Lipoproteins, as well as proprotein convertase subtilisin/kexin type 9 (PCSK9), have been shown to play a key role in the innate immune response. However, knowledge about the role and kinetics of PCSK9 in human inflammation is currently insufficient. This study aimed to investigate the interaction between inflammation and lipid metabolism, including the possible role of PCSK9. A single-blinded, placebo-controlled cross-over study using the human endotoxin model was performed.

MHMatthias Wolfgang Heinzl
Matthias Wolfgang Heinzl
LKLisa Judith Kolenchery
Lisa Judith Kolenchery
MRMichael Resl
Michael Resl
CKCarmen Klammer
Carmen Klammer
ABAnne Black
Anne Black
MCMartin Clodi
Martin Clodi
Background: Although vaccination against COVID-19 is highly effective, breakthrough infections occur, often leading to severe courses and death. The extent of protection provided by individual antibody levels in breakthrough infections is still unknown and cut-off levels have yet to be determined. Methods: In 80 consecutive fully vaccinated patients hospitalized between August and December 2021 with COVID-19 breakthrough infection (Delta variant), anti-CoV2S antibody levels were analyzed for the endpoint of death. Results: Ten out of the 12 patients who died (83.3%) had antibody levels < 600 U/mL; 5 (41.7%) of these had antibody levels < 200 U/mL. Only 2 patients with a level of >600 U/mL died from vaccine breakthrough infection. Correction for the number of comorbidities and age revealed that anti-CoV2S antibody levels at the time of hospitalization were a significant predictor for reduced risk of death (OR = 0.402 for every 1000 U/mL, p = 0.018). Conclusions: In this retrospective data analysis, we show that almost all patients who died from COVID-19 vaccine breakthrough infection had antibody levels < 600 U/mL, most of them below 200 U/mL. In logistic regression corrected for the number of comorbidities and age, anti-CoV2S antibody levels at the time of hospitalization proved to be a significantly protective predictor against death.

19 July 2022 in Shock
Verified
Journal Article
Open access
MHMatthias Wolfgang Heinzl
Matthias Wolfgang Heinzl
MRMichael Resl
Michael Resl
CKCarmen Klammer
Carmen Klammer
PFPaul Fellinger
Paul Fellinger
LSLukas Schinagl
Lukas Schinagl
MCMartin Clodi
Martin Clodi
Background: Current means of diagnosis of acute kidney injury (AKI) based on serum creatinine have poor sensitivity and may miss possible therapeutic windows in subclinical kidney injury, especially in septic AKI. Kidney injury molecule-1 (KIM-1) may be a valuable biomarker to improve diagnostic algorithms for AKI. The understanding of septic AKI is still insufficient, and knowledge about KIM-1 kinetics in inflammation is scarce. The aim of this study was to investigate the possible effect of lipopolysaccharide (LPS) on KIM-1 as a marker of structural kidney injury in healthy volunteers. Methods: A single-blinded, placebo-controlled cross-over study using the human endotoxin model (LPS administration) was performed in 10 healthy men. Kidney injury molecule-1 and serum creatinine were measured repetitively for 48 hours. Results: We observed a significant elevation of serum KIM-1 levels after the administration of LPS (P < 0.001). Furthermore, LPS caused a significant elevation of serum creatinine at an early time point (P = 0.013) as compared with placebo. Conclusion: Even a relatively small inflammatory stimulus is sufficient to cause subclinical structural kidney injury with elevated KIM-1 and serum creatinine in healthy volunteers. This outlines the insufficiency of the current diagnostic approach regarding AKI and the urgency to develop novel diagnostic algorithms including markers of kidney injury. Clinical Trial Registration: www.clinicaltrials.gov. Unique identifier: NCT03392701 (August 1, 2018)

8 April 2014 in Vox Sanguinis
Verified
Journal Article
Closed access
PDF file
MSM. Schönbacher
M. Schönbacher
MHMatthias Wolfgang Heinzl
Matthias Wolfgang Heinzl
EDE.‐M. Dauber
E.‐M. Dauber
WMW. R. Mayr
W. R. Mayr
SPS. Panzer
S. Panzer
GKG. F. Körmöczi
G. F. Körmöczi

28 November 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MHMatthias Wolfgang Heinzl
Matthias Wolfgang Heinzl
MFMarkus Freudenthaler
Markus Freudenthaler
PFPaul Fellinger
Paul Fellinger
LKLisa Judith Kolenchery
Lisa Judith Kolenchery
MRMichael Resl
Michael Resl
MCMartin Clodi
Martin Clodi
Background: Although it is known that high-density lipoprotein (HDL) exerts important anti-inflammatory effects and that low HDL plasma concentrations represent a negative prognostic marker in bacterial infections and sepsis, not much is known about possible implications of HDL in acute viral infections such as influenza. Methods: We performed a retrospective, single-centre analysis of influenza patients hospitalised during the 2018/19 and 2019/20 influenza seasons and analysed the impact of HDL concentrations on inflammation and mortality. Results: 199 influenza patients (173 male patients) were admitted during the 2018/19 and 2019/20 influenza seasons with a mortality rate of 4.5%. HDL was significantly lower in deceased patients (median HDL 21 (IQR 19–25) vs. 35 (IQR 28–44) mg/dL; p = 0.005). Low HDL correlated with increased inflammation and HDL was an independent negative predictor regarding mortality after correction for age and the number of comorbidities both overall (OR = 0.890; p = 0.008) and in male patients only (OR = 0.891; p = 0.009). Conclusions: Low HDL upon hospital admission is associated with increased inflammation and is an independent predictor for increased mortality in male patients with influenza A.

Verified
Journal Article
Open access
PDF file
MHMatthias Wolfgang Heinzl
Matthias Wolfgang Heinzl
MRMichael Resl
Michael Resl
JKJörg Kellermair
Jörg Kellermair
CSClemens Steinwender
Clemens Steinwender
BMBernhard Mayr
Bernhard Mayr
MCMartin Clodi
Martin Clodi
Background: The intrahospital prevalence of diabetes and prediabetes is not well known in Austria and worldwide. Screening for diabetes in hospitalised patients requires systematic glycaemic assessment via HbA1c measurement, which is not routinely performed in all patients in most hospitals. This study is the first multicentre investigation to conduct structured HbA1c screening in hospitalised adult medical patients of all ages. Methods: In this exploratory multicentre analysis, HbA1c screening was performed in 3025 consecutive patients hospitalised at three different medical departments in Upper Austria. HbA1c screening was conducted over a period of three months between October 2023 and March 2024. Patients were diagnosed with diabetes (HbA1c ≥6.5% (≥48 mmol/mol)) or prediabetes (HbA1c 5.7–6.4% (39–47 mmol/mol)) based on HbA1c values or a previous diagnosis. Results: Dysglycaemia (diabetes or prediabetes) was identified in 1557 patients (51.5%). Diabetes was present in 840 patients (27.8%) and prediabetes in 717 patients (23.7%). A first-time diagnosis of diabetes was made in 73 patients (2.4%). The prevalence of diabetes was highest among patients aged 70–79 years (36.8% diabetes; 24.8% prediabetes). Conclusions: Structured HbA1c screening in 3025 consecutive hospitalised patients across three medical departments in Upper Austria revealed a diabetes prevalence of 27.8% and a prediabetes prevalence of 23.7%. Overall, dysglycaemia was present in 51.5% of hospitalised patients.